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their pain. Their pain intensity during last episode of painwas 5 on
a 10-point Numeric Rating Scale (NRS). 39% of the respondents
had moderate pain (NRS = 5–7), 43% had severe pain (NRS = 7),
67% had headaches, 22% had back pain. 96% of the acute pain
sufferers were using drugs for last three months. 96% of them
were taking Aspirin® (acetyl salicilic acid), 91% Vermidon®
(paracetamol), 90% Novalgin® (Dipyrone), and 80% Apranax®
(naproxen sodium). CONCLUSION: Six percent of Turkish
adults had acute pain. Sixty-seven percent of the respondents who
had acute pain had accompying disease causing the pain. Pain is a
major health care problem in Turkey that needs to be evaluated
and researched in depth.
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A COST MINIMIZATION ANALYSIS OF IV BOLUSVERSUS IV
INFUSION DICLOFENAC IN POST-OPERATIVE PAIN
Wallerstein KRB
Pharma Focus, Belle Mead, NJ, USA
OBJECTIVES: There are two forms of injectable IV diclofenac
available (Dyloject bolus and Voltarol infusion). We conducted a
cost minimization analysis to determine the total cost of each
treatment strategy. METHODS: A decision-analytic model was
developed to estimate total treatment costs of IV bolus versus IV
infusion diclofenac. The modeled population was patients who
post-operatively would require injectable NSAIDs to control their
pain. The model timeframe was for the duration that a patient
required post-operative pain management with injectable medi-
cation. The model inputs included the actual/estimated cost of
medicines, the cost of the IV administration process (staff time and
consumables), and the cost of treating adverse events (staff time,
medicines and consumables). The unit costs and resources are
based on UK data. The results are expressed as Pounds Sterling
and as average cost per patient. One-way sensitivity analyses were
also conducted on key parameters. RESULTS: The total cost of
treating post-operative pain was less with IV bolus diclofenac
(Dyloject) than with IV infusion diclofenac (Voltarol). Diclofenac
IV bolus cost a mean27.84 per patient overall versus diclofenac
IV infusion mean cost of 78.61 per patient. The difference in
overall cost is attributable to the cost ofNSAIDs (IV bolus12.19
versus 1.69 IV Infusion), the cost of administering the NSAID
(IV bolus 9.72 versus 49.73 IV Infusion) and the cost of
consumables (IV bolus 1.40 versus 16.72 IV infusion). The
difference in the costs of rescuemedication (IV bolus2.48 versus
6.14 IV infusion) and of treating adverse events (IV bolus
2.061 versus 4.33 IV infusion) was less. One-way sensitivity
analyses show the results are sensitive to the cost of staff time and
consumables. CONCLUSION: Diclofenac IV bolus (Dyloject) is
cost saving relative to diclofenac IV infusion (Voltarol) in the
treatment of post-operative pain.
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EXPECTED COST AND COST CONSIDERATIONS
ASSOCIATED WITH OPIOID ROTATION FOR CHRONIC
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OBJECTIVES: To develop an expected-cost model to examine
the impact of opioid rotation among patients with chronic non-
cancer pain from the payor perspective METHODS: A decision
tree was developed depicting pathways a patient may follow over
the course of 1 year while taking long acting opioids. Up to 2
switches and 5 dose adjustments were possible for each of the
three treatment arms: 1) MS Contin ER switch to OPANA ER; 2)
MS Contin ER switch to OxyContin ER; and 3) OPANA ER
switch to OxyContin ER for patients where morphine is not an
appropriate ﬁrst line treatment option. Cost data included drug
acquisition costs for extended release (ER) and immediate release
(IR) opioids, physician contact reimbursement for pain special-
ists and primary care physicians. Estimated rates for side effects
were assumed similar for the most frequently reported side effects
(constipation, nausea, somnolence and sedation) and were
applied to all treatment arms. RESULTS: A total of 149 possible
pathways of care were evaluated among the 3 treatment arms.
Assuming a BID regimen, expected-cost range for treatments 1,
2, and 3 were: $3426–$4299, $3829–$5073, and $4556–$5098,
respectively. IR cost contribution of the total expected-cost for
treatment arms 1, 2, and 3 amounted to 17%, 21% and 24%,
respectively, and was dependent on the total daily ER dose.
CONCLUSION: Opioid rotation is thought to be the result of
the need to switch opioids when a therapy is not well tolerated by
the patient. Having an effective alternative for rotation/switching
if ﬁrst line treatment fails has the potential to reduce incremental
down stream costs by decreasing physician contacts due to dose
adjustment or the need for further switching. Furthermore, the
lack of effective pain management combined with non-tolerated
side effects may also require the need for additional medications
for pain (IR) and side effects.
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OBJECTIVES: To analyze health and non-health resources utili-
zation and derived costs of treating treating refractory painful
Radiculopathy followed in PCS under routine medical practice.
METHODS: A 12-weeks cross-sectional and retrospective analy-
sis was carried out in year 2006 in a whole-nation representative
sample of PC centres. Men and women above 18 years, with
chronic pain (6-month or more) due to cervical (17%) or lumbar
(83%) radiculopathy, refractory to, at least, one previous anal-
gesic were included in the analysis. Health resources included
all-type medical visits, hospitalizations, complementary test and
pharmacological and non-pharmacological therapies. Non-
health included wages loses due to loss-work-days equivalents
(LWDE = absenteeism days + days working with reduced pro-
ductivity due to pain). Pain severity was measured by McGill-
pain scale. RESULTS: One-thousand-four-hundred-ﬁfty-two
subjects [55.8% women, 56.7 (12.5) years] with cervical or
lumbar radiculopathy were analyzed. Last-week mean pain
severity was 71.4 (15.1) mm with 61.4% declaring the pain as
severe or worst the day of collecting data. Previous mean (SD)
number of drugs was 2.6 (1.4), with a 24.0% on one-drug only;
81% on NSAIDs, 47% on paracetamol, 32% on opiods, 17% on
muscle-relaxants, 9% on antiepileptics, and 7% on antidepres-
sants. Quarterly mean LWDE was 41.1 (28.6) days. Medical
visits average per trimester was 9.1 (6.2), with 3.9% declaring
one-hospitalization. Quarterly total mean cost was €2970
(2114); €1032 (1207) direct health cost and €1938 (1490) indi-
rect cost. CONCLUSION: In the primary care setting, health and
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non-health resources utilization under routine medical practice
derived in substantial costs when treating refractory painful due
to cervical or lumbar radiculopathy. About two-thirds of the
total costs were derived from non-health resources.
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OBJECTIVES: To analyze the Pregabalin (PGB) effect under
routine medical practice on longitudinal health and non-health
resources utilization (HRU) and derived costs of treating refrac-
tory painful Radiculopathy in Primary Care Setting (PCS) during
12-weeks. METHODS: A representative sample of PC centres
included men and women above 18 years, with chronic pain
(6-month or more) due to cervical (17%) or lumbar (83%)
radiculopathy refractory to, at least, one previous analgesic [mean
(SD) number of drugs; 2.6 (1.4)], in a prospective, naturalistic,
12-weeks two-visit study. Health resources included all-type
medical visits, hospitalizations, complementary test and pharma-
cological and non-pharmacological therapies. Non-health
included wages loses due to loss-work-days equivalents
(LWDE = absenteeism days + days working with reduced produc-
tivity due to pain). Pain severity was measured by McGill-pain
scale. Descriptive statistics and ANCOVA models were applied
to compare 12-weeks periods of treatment. RESULTS: One-
thousand-three-hundred-ﬁfty-one PGB-naive patients [55.8%
women, 56.7 (12.5) years] were analyzed: 490 (36%) switched to
PGB as monotherapy (PGBm), 702 (52%) patients received PGB
as add-on therapy (PGBadd-on), and in 159 (12%) previous
treatment was replaced by a regimen not including PGB (Non-
PGB). As compared to non-PGB, both PGBm and PGBadd-on
showed signiﬁcantly higher HRU reduction. The extra costs of
drugs, particularly in PGB subgroups [€15.4 (39.1), €148.6
(109.1) and €145.3 (119.6), respectively (p < 0.0001 within and
between groups)] was off-set by higher signiﬁcant reductions in all
other components of health costs (except non-pharmacological
therapies in non-PGB group) yielding to a greater total cost
reductions: €1203.3 (1805.6), €1423.2 (1650.0) and €1429.2
(1966.2), respectively (p < 0.001 within and p = 0.0004 between
groups). CONCLUSION: In the primary care setting either
add-on or monotherapy with pregabalin under routine medical
practicewas associatedwith a signiﬁcant longitudinal reduction in
HRU and total costs when compared with non-PGB therapy in
subjects with painful radiculopathy of cervical or lumbar origin.
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OBJECTIVES: To analyze health and non-health resources utili-
zation and derived costs of treating patients with refractory
peripheral NeP followed in PCS under routine medical practice.
METHODS: A 12-weeks cross-sectional and retrospective analy-
sis was carried out in year 2006 in a whole-nation representative
sample of PC centres. Men and women above 18 years, with
chronic pain (6-month or more) due to peripheral NeP (diabetic
neuropathy, post-herpetic neuralgia or trigeminal neuralgia), and
refractory to, at least, one previous analgesic were included in the
analysis. Health resources included all-type medical visits, hos-
pitalizations, complementary test and pharmacological and non-
pharmacological therapies. Non-health included wages loses due
to loss-work-days equivalents (LWDE = absenteeism days + days
working with reduced productivity due to pain). Pain severity
was measured by McGill-pain scale. RESULTS: One-thousand-
four-hundred-thirty-nine subjects [58.8% women, 59.5 (12.7)
years] were analyzed: 783 (54%) with diabetic painful neuropa-
thy (DPN), 486 (34%) with post-herpetic neuralgia (PHN), and
170 (12%) with trigeminal neuralgia (TN). Last-week mean pain
severity was 70.8 (16.1) mm with 60.2% declaring the pain as
severe or worst the day of collecting data. Previous mean (SD)
number of drugs was 2.3 (1.3), with a 30.3% on one-drug only;
72% on NSAIDs, 43% on paracetamol, 36% on opiods, 23% on
antiepileptics, and 11% on antidepressants. Quarterly mean
LWDE was 37.5 (27.6) days. Medical visits average per trimester
was 9.7 (7.6), with 4.4% declaring one-hospitalization. Quar-
terly total mean cost was €2689 (2236); €983 (1394) direct
health cost and €1706 (1440) indirect cost. Cost and health
resources utilization were not associated to aetiological cause of
pain. CONCLUSION: In the primary care setting, health and
non-health resources utilization under routine medical practice
derived in substantial costs when treating the associated refrac-
tory pain to peripheral neuropathies due to diabetes, post-
herpetic or trigeminal neuralgia. Two-thirds of the total costs
were derived from non-health resources.
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RESULTS FROM A PROSPECTIVE STUDY ON PATIENTS WITH
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OBJECTIVES: In this prospective study, we captured resource
utilization and work productivity due to breakthrough pain
(BTP). METHODS: The sample consisted of outpatients at a
large U.S. academic medical center who had chronic pain due to
headache, musculoskeletal problems, arthritis/rheumatism, and
sickle cell anemia. Patients were administered a 1-week diary
which captured demographics, disability, pain (10-point VAS),
resource utilization due to BTP (hospitalizations, emergency
room visits, outpatient visits, and calls to physician ofﬁces), and
work productivity (Health-Related Productivity Questionnaire-
Diary). RESULTS: Among the 161 patients enrolled, 142
reported at least 1 BTP ﬂare during the diary week (90.5%). Of
these, 36 suffered from chronic headache (25.3%), 16 from
arthritis/rheumatism (11.3%), 16 from sickle cell anemia
(11.3%), 9 from musculoskeletal problems (6.3%), and 1 from
neuropathy (0.7%). The remainder reported 2 or more painful
conditions (45.1%; n = 64). The cohort experienced 2561 BTP
ﬂares (mean per patient per week = 18). Mean pain levels were
5.3 for headache, 5.2 for arthritis/rheumatism, 6.2 for sickle cell
anemia, 6.8 for musculoskeleletal problems, and 6 for those with
2 or more painful conditions. BTP ﬂares resulted in 8 hospital-
izations, 9 emergency room visits, 30 outpatient medical visits,
and 24 calls to physician ofﬁces during the diary week and
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